AxioSonic

AxioSonic is a medical technology company developing a non-invasive, wearable focused ultrasound platform designed to temporarily and reversibly open the blood-brain barrier (BBB). The company's technology utilizes low-intensity ultrasound in combination with microbubbles to facilitate the targeted delivery of therapeutic agents—ranging from small molecules to large antibodies—directly into the central nervous system. By overcoming the physiological hurdle of the BBB, AxioSonic aims to transform the treatment landscape for neurodegenerative disorders such as Alzheimer's and Parkinson's, as well as primary brain tumors like glioblastoma. The platform is designed to be modality-agnostic, enhancing the brain penetration of various drug classes that are otherwise restricted from the brain parenchyma.